ABBVAbbVieSigning up patients
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer · Neoadjuvant
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 140 (planned)
- Started
- Nov 21, 2025
- Main results expected
- Feb 2030
- Fully finished
- Feb 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response (OR) by Independent Central Review (ICR)
Measured over: Up to Approximately 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06890338 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC